Is It A Buyer's Market For Private Biotech Deals? – Forbes


Forbes

Is It A Buyer’s Market For Private Biotech Deals?
Forbes
Although pharmas have historically sought “de-risked” drug candidates, more recently deal-making has shifted to earlier stages of development. So, are today’s Phase 2 drugs actually attractive, or are they what’s left over after the most desirable

Read More…

Share This: